CG Oncology Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CGON research report →
About the company
CG Oncology, Inc. , a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC.
- CEO
- Arthur Kuan
- IPO
- 2024
- Employees
- 142
- HQ
- Irvine, CA, US
Price Chart
- Market Cap
- $6.21B
- P/E
- -30.07
- P/S
- 1223.81
- P/B
- 5.45
- EV/EBITDA
- -33.50
- Div Yield
- 0.00%
- Gross Margin
- -664.82%
- Op Margin
- -4238.99%
- Net Margin
- -3682.61%
- ROE
- -23.33%
- ROIC
- -19.52%
- Revenue
- $4.04M · 254.70%
- Net Income
- $-160,995,000 · -82.87%
- EPS
- $-2.08 · -47.52%
- Op Income
- $-190,774,000
- FCF YoY
- -67.81%
- 52W High
- $77.00
- 52W Low
- $23.65
- 50D MA
- $64.65
- 200D MA
- $53.56
- Beta
- 0.31
- Avg Volume
- 1.09M
Get TickerSpark's AI analysis on CGON
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 25, 26 | Liu Brian Guan-Chyun | buy | 371,085 |
| Jun 24, 26 | POST LEONARD E | other | 5,000 |
| Jun 24, 26 | POST LEONARD E | other | 5,000 |
| Jun 24, 26 | POST LEONARD E | sell | 5,000 |
| Jun 22, 26 | POST LEONARD E | other | 5,000 |
| Jun 22, 26 | POST LEONARD E | other | 5,000 |
| Jun 22, 26 | POST LEONARD E | sell | 5,000 |
| Jun 15, 26 | Mulay James | other | 1,310 |
| Jun 15, 26 | Mulay James | other | 1,310 |
| Jun 15, 26 | Mulay James | other | 654 |
Our CGON coverage
Recent articles, reports, and earnings notes.
No research on CGON yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CGON report →Similar companies
Peers in the same neighborhood.